Hakan Goker
Managing Director at M Ventures, Head of Biotechnology Investments, Amsterdam, The Netherlands
Hakan Goker is the Managing Director, and heads the Biotechnology team responsible for Healthcare and Life Sciences investments of M Ventures, the strategic venture capital fund of Merck KGaA, Darmstadt, Germany. A venture investor for 15 years, starting at Atlas Venture, continuing at Aescap Venture, joining M Ventures in 2013, Hakan has been instrumental in the formation, management and business strategy of multiple companies globally throughout his tenure including Artios Pharma, Orphazyme, f-Star, Bicycle Therapeutics, Nimbus Discovery, Storm Therapeutics, and Ribometrix.
M Ventures’ mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From the headquarters in Amsterdam, Netherlands, and offices in the US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs, takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.